Top Ten most popular articles on Pharmafile.com this week!
pharmafile | December 14, 2018 | News story | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | Akorn, Boehringer, Novartis, Pfizer, Trump, UK, pharmafile, top 10
Business seemed to be the theme this week as Akorn’s acquisition of Fresenius fell through, while Boehringer announced a restructuring through which 300 jobs would be lost. However our top story covered Novartis’ CEO Vasant Narasimhan’s comments on creating a more millennial friendly culture within the Swiss multinational.
Nevertheless our feature on developments being made in the area of MDMA-assisted psychotherapy was popular after positive Phase 2 results were released in November of this year.
Check out this week’s ten most popular stories on Pharmafile.com!
The Trump Administration has halted the acquisition of new human foetal tissue for use in experiments conducted by NIH researchers, thus disrupting research into a cure for HIV.
9. Akorn CEO resigns after $4.3bn Fresenius deal falls through
The CEO of American generics firm Akorn Inc has stepped down following a ruling from the Delaware Supreme Court declaring that a rapid downturn in Akorn’s business was reason enough for German company Fresenius to walk away from a $4.3 billion dollar acquisition.
8. WHO confirm Tanzania FDA as Africa’s first well-functioning regulatory body
Tanzania has become the first country in Africa to achieve a well-functioning regulatory system for medical products, according to the World Health Organization (WHO).
7. Feature – Psychedelic therapy: A new approach to mental health
In November 2018, a Phase 2 clinical trial found that 76% of patients who underwent MDMA-assisted psychotherapy no longer had PTSD, twelve months after undergoing treatment. Louis Goss looks into the process through which an underground therapy entered FDA approved clinical trials.
6. Atopic dermatitis market set to almost triple in value over next 10 years
The atopic dermatitis (eczema) market is expected to reach $18.3 billion by 2027, according to analytics firm GlobalData.
At least 16 generic drugmakers are being investigated for their involvement in what has been described as the “largest cartel in the history of the United States”.
4. Boehringer’s France restructure will cull over 300 jobs
Boehringer Ingelheim is set to follow in the recent steps of Sanofi with the announcement of a cull of over 300 employees in France – around 10% of the company’s total workforce in the country.
3. Pfizer announces new UK Managing Director
New York City-based multinational Pfizer has announced the appointment of Ben Osborn to the role of managing Director in the UK and Cluster Lead Europe within Pfizer’s Established Medicines business.
2. Pfizer’s palbociclib most commonly used breast cancer drug in clinical trials
Pfizer’s palbociclib is the most commonly used breast cancer drug in clinical trials, according to analytics firm GlobalData.
1. Novartis CEO calls for cultural shift to cater for millennial generation
The CEO of Swiss multinational Novartis has said that he wants to ‘un-boss’ the multi-billion pound company while relaxing the firm’s rules by allowing employees to wear jeans to work.
Related Content
Novartis shares new data about Fabhalta for IgAN treatment
Novartis has announced new results from a pre-specified interim analysis of its phase 3 APPLAUSE-IgAN …
Novartis shares new data for Zolgensma in children with SMA
Novartis has announced new data to continue the support of the clinical benefits of Zolgensma …
Pfizer’s Velsipity approved by EC for ulcerative colitis treatment
Pfizer has announced that the European Commission (EC) has granted marketing authorisation for Velsipity (etrasimod) …
